Description

Rifater is a fixed-dose combination pharmaceutical product used in the treatment of tuberculosis. This formulation is critical for ensuring patient adherence to complex multi-drug regimens, which is a cornerstone of effective TB control programs. It is primarily required by pharmaceutical manufacturers, global health procurement agencies, and national tuberculosis programs seeking reliable, high-quality, and compliant anti-tuberculosis medications.

Application

• First-line tuberculosis treatment as part of a directly observed therapy (DOT) strategy.
• Pharmaceutical manufacturing for the production of standardized combination tablets.
• Public health initiatives and procurement for national TB control programs.
• Clinical use in the intensive phase of active, drug-susceptible pulmonary tuberculosis.
• Supply to non-governmental organizations (NGOs) and aid groups operating in high-burden regions.

Basic Information

Product Name	Rifater
CAS No.	161935-14-4
Molecular Formula	Combination Product
Molecular Weight	N/A (Combination)
Synonyms	Rifampin/Isoniazid/Pyrazinamide; Rifater Tablet; Rifampicin/Isoniazid/Pyrazinamide; RIF/INH/PZA; Anti-TB Triple Drug Combination; RHZ; Rifampin, Isoniazid, and Pyrazinamide Tablets; Tuberculosis Combination Therapy
EINECS	Contact for details

Quality Control

Our Rifater is manufactured under strict Good Manufacturing Practices (GMP) and controlled to meet the relevant pharmacopoeial standards (e.g., USP, BP, EP) for each active pharmaceutical ingredient (API). Every batch undergoes rigorous quality testing including assay, dissolution, content uniformity, and identification of all components. Certificates of Analysis (COA) are available upon request, and we support audits for regulatory compliance.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, 15-30°C (59-86°F). Protect from moisture and excessive heat.

Specification

Item	Specification
Description	Film-coated tablet
Identification (HPLC/IR)	Conforms to standard
Assay (Rifampin)	90.0% - 110.0% of label claim
Assay (Isoniazid)	90.0% - 110.0% of label claim
Assay (Pyrazinamide)	90.0% - 110.0% of label claim
Dissolution	Conforms to pharmacopoeial requirements
Content Uniformity	Meets USP/EP requirements
Related Substances	Conforms to individual API monographs
Water Content (KF)	< 5.0%
Microbial Limits	Conforms to USP/EP

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.